首页 正文

Targeting p300 Reverses Acidic Microenvironment-Induced PARP Inhibitor Resistance

{{output}}
Poly(ADP-ribose) polymerase inhibitors (PARPi) are a first-line treatment for epithelial ovarian cancer (EOC) patients, but the development of resistance limits long-term therapeutic efficacy. Tumor acidosis is a hallmark of the tumor microenvironment that has... ...